VolitionRx (NYSE:VNRX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note released on Tuesday. The brokerage issued a sell rating on the stock.

VNRX has been the subject of several other research reports. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd. D. Boral Capital reissued a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research report on Tuesday, December 10th.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.66 on Tuesday. VolitionRx has a one year low of $0.43 and a one year high of $1.23. The business’s 50-day moving average price is $0.65 and its two-hundred day moving average price is $0.66. The company has a market capitalization of $61.16 million, a P/E ratio of -1.83 and a beta of 1.20.

Insider Transactions at VolitionRx

In related news, CEO Cameron John Reynolds bought 139,811 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was purchased at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the purchase, the chief executive officer now directly owns 2,117,404 shares in the company, valued at $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the completion of the transaction, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 358,266 shares of company stock worth $204,212. 12.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC raised its position in VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent SEC filing. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.